Dr. Levine on Sequencing of Agents for Ovarian Cancer

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the sequencing of agents for patients with ovarian cancer.

Due to precision medicine, sequencing is quite easy, explains Levine. However, it is the interpretation of the sequencing that is more challenging. For newer laboratories, it is important to understand how the validation is done and ensure that the details of the sequence analysis are done well.

It is possible to use the sequencing to determine what mutation is in the tumor, and then refer that patient towards a clinical trial or off-label use of clinical therapies.